Inhibrx has been granted a patent for VHH-containing polypeptides that bind CD123, with potential uses outlined. The patent includes an immunoconjugate combining VHH domains binding CD123 with cytotoxic agents, featuring specific amino acid sequences. GlobalData’s report on Inhibrx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Inhibrx Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Inhibrx, Personalized cancer vaccines was a key innovation area identified from patents. Inhibrx's grant share as of February 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Immunoconjugate comprising vhh domain binding cd123 and cytotoxic agent

Source: United States Patent and Trademark Office (USPTO). Credit: Inhibrx Inc

A recently granted patent (Publication Number: US11919963B2) discloses an immunoconjugate designed for targeted cancer therapy. The immunoconjugate comprises a polypeptide with at least one VHH domain that binds to CD123, a protein often overexpressed in cancer cells, along with a cytotoxic agent. The VHH domain sequences are specified in the claims, ensuring high specificity and efficacy in targeting CD123. Additionally, the patent mentions the humanization of VHH domains and the inclusion of an Fc region in the polypeptide, which can form dimers under physiological conditions, enhancing the therapeutic potential of the immunoconjugate.

Moreover, the patent covers a method of treating cancer by administering the immunoconjugate to patients with various types of lymphomas, leukemias, and other cancers where CD123 is a viable target. The patent also includes provisions for combining the immunoconjugate with other anti-cancer therapies like chemotherapeutic agents, biologics, radiation therapy, CAR-T therapy, or oncolytic viruses for a synergistic effect. Furthermore, the patent extends to isolated T cells engineered to express VHH domains targeting CD123, offering a novel approach to cancer immunotherapy. These engineered T cells, including CAR-T cells, can be used in personalized cancer treatment strategies, potentially revolutionizing the field of oncology with their targeted and potent anti-cancer effects.

To know more about GlobalData’s detailed insights on Inhibrx, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies